Dugel Pravin 4

What Happened

• Pravin Dugel (Executive Chairman, President and CEO) sold 124,882 shares of Ocular Therapeutix (OCUL) on 2026-02-12. The weighted-average price reported was $9.04, for an aggregate proceeds of approximately $1,128,933. The filing lists the transaction as a sale (code S).

Key Details

• Transaction date: 2026-02-12; filing date: 2026-02-17 (filed 5 days after the trade; typically Form 4s are due within two business days).
• Price: weighted average $9.04; individual trades ranged from $8.9900 to $9.0850 (per footnote).
• Total shares sold: 124,882; total proceeds ≈ $1,128,933.
• Shares owned after transaction: Not stated in the provided excerpt of the filing.
• Footnotes: Footnote 1 explains these shares were sold pursuant to a durable automatic sell-to-cover instruction to satisfy tax withholding on RSUs that vested 2026-02-11 — the sales were not a discretionary trade by the reporting person. Footnote 2 notes the reported price is a weighted average and the filer can provide a per-trade breakdown upon request.

Context

• This was a sell-to-cover tax withholding transaction tied to RSU vesting (routine administrative sale), not an open-market discretionary sale for investment purposes. Such sell-to-cover transactions are common when restricted stock units vest and the holder uses part of the shares to cover taxes.